collection
https://read.qxmd.com/read/36776780/real-world-use-of-bezlotoxumab-and-fecal-microbiota-transplantation-for-the-treatment-of-clostridioides-difficile-infection
#1
JOURNAL ARTICLE
Sofía de la Villa, Sergio Herrero, Patricia Muñoz, Carmen Rodríguez, Maricela Valerio, Elena Reigadas, Ana Álvarez-Uría, Luis Alcalá, Mercedes Marín, María Olmedo, Martha Kestler, Esther Chamorro, Emilio Bouza
BACKGROUND: We aimed to describe the frequency of use and effectiveness of bezlotoxumab (BZX) and fecal microbiota transplantation (FMT) in patients with Clostridioides difficile infection (CDI) in real-world practice. METHODS: This was a retrospective study conducted in a university hospital in which adult patients treated with BZX or FMT from January 2018 to April 2021 were included. The primary objective was to evaluate the effectiveness of BZX and FMT in preventing early (within 8 weeks) and late (within 1 year) CDI recurrences (rCDI)...
February 2023: Open Forum Infectious Diseases
https://read.qxmd.com/read/37042243/strategies-to-prevent-clostridioides-difficile-infections-in-acute-care-hospitals-2022-update
#2
JOURNAL ARTICLE
Larry K Kociolek, Dale N Gerding, Ruth Carrico, Philip Carling, Curtis J Donskey, Ghinwa Dumyati, David T Kuhar, Vivian G Loo, Lisa L Maragakis, Monika Pogorzelska-Maziarz, Thomas J Sandora, David J Weber, Deborah Yokoe, Erik R Dubberke
No abstract text is available yet for this article.
April 2023: Infection Control and Hospital Epidemiology
https://read.qxmd.com/read/36419222/pathogenicity-and-virulence-of-clostridioides-difficile
#3
REVIEW
Jessica E Buddle, Robert P Fagan
Clostridioides difficile is the most common cause of nosocomial antibiotic-associated diarrhea, and is responsible for a spectrum of diseases characterized by high levels of recurrence, morbidity, and mortality. Treatment is complex, since antibiotics constitute both the main treatment and the major risk factor for infection. Worryingly, resistance to multiple antibiotics is becoming increasingly widespread, leading to the classification of this pathogen as an urgent threat to global health. As a consummate opportunist, C...
December 2023: Virulence
https://read.qxmd.com/read/34678515/european-society-of-clinical-microbiology-and-infectious-diseases-2021-update-on-the-treatment-guidance-document-for-clostridioides-difficile-infection-in-adults
#4
JOURNAL ARTICLE
Joffrey van Prehn, Elena Reigadas, Erik H Vogelzang, Emilio Bouza, Adriana Hristea, Benoit Guery, Marcela Krutova, Torbjorn Norén, Franz Allerberger, John E Coia, Abraham Goorhuis, Tessel M van Rossen, Rogier E Ooijevaar, Karen Burns, Bente R Scharvik Olesen, Sarah Tschudin-Sutter, Mark H Wilcox, Maria J G T Vehreschild, Fidelma Fitzpatrick, Ed J Kuijper
SCOPE: In 2009, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first treatment guidance document for Clostridioides difficile infection (CDI). This document was updated in 2014. The growing literature on CDI antimicrobial treatment and novel treatment approaches, such as faecal microbiota transplantation (FMT) and toxin-binding monoclonal antibodies, prompted the ESCMID study group on C. difficile (ESGCD) to update the 2014 treatment guidance document for CDI in adults...
December 2021: Clinical Microbiology and Infection
https://read.qxmd.com/read/32441243/clostridioides-difficile-in-covid-19-patients-detroit-michigan-usa-march-april-2020
#5
LETTER
Avnish Sandhu, Glenn Tillotson, Jordan Polistico, Hossein Salimnia, Mara Cranis, Judy Moshos, Lori Cullen, Lavina Jabbo, Lawrence Diebel, Teena Chopra
We describe 9 patients at a medical center in Detroit, Michigan, USA, with severe acute respiratory syndrome coronavirus 2 and Clostridioides difficile. Both infections can manifest as digestive symptoms and merit screening when assessing patients with diarrhea during the coronavirus disease pandemic. These co-infections also highlight the continued importance of antimicrobial stewardship.
September 2020: Emerging Infectious Diseases
https://read.qxmd.com/read/32482380/three-different-patterns-of-positive-clostridium-difficile-laboratory-tests-a-comparison-of-clinical-behavior
#6
COMPARATIVE STUDY
María Olmedo, Luis Alcalá, Maricela Valerio, Mercedes Marín, Raffaella Onori, Elena Reigadas, Patricia Muñoz, Emilio Bouza
Clostridium difficile (CD) diagnosis is very varied and under discussion. Different research groups disagree on the clinical significance of patients with negative direct toxin and positive polymerase chain reaction (PCR) or even more with direct toxin and glutamate dehydrogenase (GDH) both negatives, but CD detected by toxigenic culture (TC). The objective was to analyze the characteristics of patients with 3 different diagnostic criteria. We compared these 3 groups of patients: group 1: (GDH+/direct toxin+/PCR+), group 2: (GDH+/direct toxin-/PCR+) and group 3: (GDH-/direct toxin-/PCR not done/TC+)...
July 2020: Diagnostic Microbiology and Infectious Disease
https://read.qxmd.com/read/32335312/role-of-clostridioides-difficile-in-hospital-environment-and-healthcare-workers
#7
JOURNAL ARTICLE
E Reigadas, S Vázquez-Cuesta, L Villar-Gómara, R Onori, L Alcalá, M Marín, P Muñoz, E Bouza
Clostridioides difficile infection (CDI) was traditionally considered to be transmitted within healthcare environment, from other patients or healthcare workers (HCW). Recently, this idea has been challenged. Our objective was to determine the extent of C. difficile contamination in hospital environment with a simplified method for C. difficile recovery. Environmental samples were taken from rooms of patients positive for CDI (Case) and negative for toxigenic C. difficile (Control). Environmental sampling was performed at the time a fecal sample was taken for CDI diagnosis, 48 h after, and 10 days after...
June 2020: Anaerobe
https://read.qxmd.com/read/32080996/recommendations-for-the-diagnosis-and-treatment-of-clostridioides-difficile-infection-an-official-clinical-practice-guideline-of-the-spanish-society-of-chemotherapy-seq-spanish-society-of-internal-medicine-semi-and-the-working-group-of-postoperative-infection
#8
JOURNAL ARTICLE
E Bouza, J M Aguado, L Alcalá, B Almirante, P Alonso-Fernández, M Borges, J Cobo, J Guardiola, J P Horcajada, E Maseda, J Mensa, N Merchante, P Muñoz, J L Pérez Sáenz, M Pujol, E Reigadas, M Salavert, J Barberán
This document gathers the opinion of a multidisciplinary forum of experts on different aspects of the diagnosis and treatment of Clostridioides difficile infection (CDI) in Spain. It has been structured around a series of questions that the attendees considered relevant and in which a consensus opinion was reached. The main messages were as follows: CDI should be suspected in patients older than 2 years of age in the presence of diarrhea, paralytic ileus and unexplained leukocytosis, even in the absence of classical risk factors...
April 2020: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://read.qxmd.com/read/31876184/presence-of-toxigenic-clostridioides-clostridium-difficile-in-edible-bivalve-mollusks-in-spain
#9
JOURNAL ARTICLE
Carmen Candel-Pérez, Elvira Zapata-Galián, Ruben López-Nicolás, Gaspar Ros-Berruezo, Carmen Martínez-Graciá
Clostridioides difficile reservoirs other than humans are becoming increasingly recognized, and the occurrence of the pathogen in shellfish raises concern because spores can survive cooking temperature and edible bivalve mollusks are often consumed raw or poorly cooked. This study was conducted to determine the occurrence of pathogenic C. difficile in retail bivalve mollusks. The microbiological quality of samples was also checked through the isolation of Salmonella spp. and Escherichia coli . We analyzed 129 mollusk samples from different fishmongers and grocery stores in Murcia...
December 26, 2019: Food Science and Technology International
https://read.qxmd.com/read/31927652/tigecycline-for-the-treatment-of-patients-with-clostridium-difficile-infection-an-update-of-the-clinical-evidence
#10
JOURNAL ARTICLE
Konstantinos S Kechagias, Stamatia Chorepsima, Nikolaos A Triarides, Matthew E Falagas
PURPOSE: Clostridium difficile infection (CDI) is the most common cause of nosocomial diarrhea in adult patients and is associated with considerable morbidity and mortality. Apart from the standard treatment regimens, tigecycline has shown significant in vitro activity against C. difficile but data regarding its clinical impact remains controversial. The aim of this article is to update the evidence related to the clinical role of tigecycline against C. difficile. METHODS: PubMed and Scopus databases were searched for relevant literature published from January 2015 to July 2018...
June 2020: European Journal of Clinical Microbiology & Infectious Diseases
https://read.qxmd.com/read/31883938/faecal-microbiota-transplantation-for-recurrent-clostridioides-difficile-infection-experience-with-lyophilized-oral-capsules
#11
JOURNAL ARTICLE
E Reigadas, E Bouza, M Olmedo, S Vázquez-Cuesta, L Villar-Gómara, L Alcalá, M Marín, S Rodríguez-Fernández, M Valerio, P Muñoz
BACKGROUND: Faecal microbiota transplantation (FMT) is a highly effective approach for refractory and recurrent Clostridioides difficile infection (CDI). Despite its excellent efficacy, FMT is not yet a routine procedure in most centres. There is very little experience with FMT based on lyophilized capsules, and data from European institutions are lacking. This article describes our experience with FMT to treat recurrent CDI using lyophilized oral capsules. METHODS: A prospectively recorded single-centre case series of patients with recurrent CDI who underwent FMT between January 2018 and May 2019 were analysed...
December 26, 2019: Journal of Hospital Infection
https://read.qxmd.com/read/31823917/statins-risk-of-clostridium-difficile-infection-a-meta-analysis
#12
JOURNAL ARTICLE
Karn Wijarnpreecha, Panadeekarn Panjawatanan, Charat Thongprayoon, Patompong Ungprasert
BACKGROUND & OBJECTIVES: Clostridium difficile infection is one of the most common healthcare-associated infections worldwide. Recent epidemiologic studies have suggested that statin users may have a lower risk of C. difficile infection, although the results are inconsistent. This meta-analysis was conducted with the aim of summarizing all available data to assess the risk of C. difficile infection among statin users versus non-users. METHODS: A literature review was performed using the MEDLINE and EMBASE databases from inception to October 2017...
October 2019: Indian Journal of Medical Research
https://read.qxmd.com/read/30588042/bezlotoxumab-for-the-prevention-of-clostridium-difficile-infection-a-review-of-current-evidence-and-safety-profile
#13
REVIEW
Carolyn D Alonso, Monica V Mahoney
Clostridium difficile infection (CDI) is a leading nosocomial disease estimated to cause nearly half a million cases in the United States annually. Recurrent CDI (rCDI) affects ~25% of patients after completion of standard of care therapy and is associated with substantial health care costs and a negative impact on patient's overall markers of quality of life. Bezlotoxumab is the first of its kind monoclonal antibody directed against C. difficile toxin B and indicated for prevention of rCDI in at-risk patients...
2019: Infection and Drug Resistance
https://read.qxmd.com/read/30615960/effect-of-using-fidaxomicin-on-recurrent-clostridium-difficile-infection
#14
JOURNAL ARTICLE
M Biggs, T Iqbal, E Holden, V Clewer, M I Garvey
Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding...
June 2019: Journal of Hospital Infection
https://read.qxmd.com/read/30561531/what-is-the-role-for-metronidazole-in-the-treatment-of-clostridium-difficile-infection-results-from-a-national-cohort-study-of-veterans-with-initial-mild-disease
#15
JOURNAL ARTICLE
Haley J Appaneal, Aisling R Caffrey, Kerry L LaPlante
BACKGROUND: Metronidazole may still be an appropriate therapeutic option for mild Clostridium difficile infection (CDI) in select patients, but data are limited to guide clinicians in identifying these patients. METHODS: Our 2-stage study included a national cohort of Veterans with a first episode of mild CDI (2010-2014). First, among those treated with metronidazole, we identified predictors of success, defined as absence of all-cause mortality or recurrence 30 days posttreatment, using multivariable unconditional logistic regression...
September 27, 2019: Clinical Infectious Diseases
https://read.qxmd.com/read/30583055/fidaxomicin-versus-oral-vancomycin-for-severe-clostridium-difficile-infection-a-retrospective-cohort-study
#16
MULTICENTER STUDY
C A Gentry, P K Nguyen, S Thind, G Kurdgelashvili, G H Skrepnek, R J Williams
OBJECTIVES: This study was conducted to compare clinical outcomes of fidaxomicin versus oral vancomycin in the management of severe Clostridium difficile infection (CDI). METHODS: The investigation was a retrospective, multicentre, propensity score-matched analysis using a national clinical administrative database. Veterans treated for severe CDI from any Veterans Affairs Medical Center between 1 June 2011 and 30 June 2017 were included if they received fidaxomicin or an oral vancomycin regimen for treatment...
August 2019: Clinical Microbiology and Infection
https://read.qxmd.com/read/30532567/pomegranate-extract-specifically-inhibits-clostridium-difficile-growth-and-toxin-production-without-disturbing-the-beneficial-bacteria-in-vitro
#17
JOURNAL ARTICLE
Murugapillai Rathinam Sukumar, Brigitte König
OBJECTIVE: The aim of this study was to assess the pomegranate juice against the growth and toxin production of multidrug-resistant Clostridium difficile hypervirulent strain NAP1/027/BI and also against the growth of beneficial bacteria to prevent or suppress C. difficile infection (CDI). MATERIALS AND METHODS: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were taken as parameters for the assessment of antimicrobial property of the pomegranate juice...
2018: Infection and Drug Resistance
https://read.qxmd.com/read/30547500/-recommendations-from-a-panel-of-experts-on-the-usefulness-of-fidaxomicin-for-the-treatment-of-infections-caused-by-clostridium-difficile
#18
JOURNAL ARTICLE
E Bouza, J Cobo, B Almirante
OBJECTIVE: Clostridium difficile infections have a high recurrence rate, which can complicate the prognosis of affected patients. It is therefore important to establish an early detection and an appropriate therapeutic strategy. The objective of this manuscript was to gather the opinion of an expert group about the predictive factors of poor progression, as well as when to use fidaxomicin in different groups of high-risk patients. METHODS: A scientific committee of three experts in infectious diseases reviewed the most recent literature on the management of C...
February 2019: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://read.qxmd.com/read/30498879/management-of-adult-clostridium-difficile-digestive-contaminations-a-literature-review
#19
REVIEW
Fanny Mathias, Christophe Curti, Marc Montana, Charléric Bornet, Patrice Vanelle
Clostridium difficile infections (CDI) dramatically increased during the last decade and cause a major public health problem. Current treatments are limited by the high disease recurrence rate, severity of clinical forms, disruption of the gut microbiota, and colonization by vancomycin-resistant enterococci (VRE). In this review, we resumed current treatment options from official recommendation to promising alternatives available in the management of adult CDI, with regard to severity and recurring or non-recurring character of the infection...
February 2019: European Journal of Clinical Microbiology & Infectious Diseases
https://read.qxmd.com/read/30400734/recurrent-clostridium-difficile-infection-risk-factors-treatment-and-prevention
#20
REVIEW
Jung Hoon Song, You Sun Kim
The most common cause of antibiotic-associated diarrhea is Clostridium difficile infection (CDI). Recurrent C. difficile infection (rCDI) often occurs after successful treatment of CDI. Due to the increased incidence and the difficulty in treating rCDI, it is becoming an important clinical issue. Identifying risk factors is helpful for early detection, treatment, and prevention of rCDI. Advanced age, use of antibiotics, gastric acid suppression, and infection with a hypervirulent strain are currently regarded as the major risk factors for rCDI...
January 15, 2019: Gut and Liver
label_collection
label_collection
6857
1
2
2018-11-15 11:16:02
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.